Aventis and Bayer call off joint venture plans

- Last updated on GMT

Related tags: Future, Medicine, Aventis

Franco-German drugmaker Aventis and Germany's Bayer have agreed not
to pursue their plans to create a joint venture in the field of
biological products.

Franco-German drugmaker Aventis and Germany's Bayer have agreed not to pursue their plans to create a joint venture in the field of biological products.

The two companies had intended to combine Aventis Behring, the therapeutic proteins business of Aventis, with the Biological products division of Bayer HealthCare. Both companies reviewed various possible forms of cooperation but a final agreement on the terms of the transaction could not be reached.

According to a statement this week Aventis is pro-actively exploring alternative options for the future of Aventis Behring.

In 2001, Aventis generated sales of € 17.7 billion and invested € 3 billion in research and development and employed.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more